In 2003, Braak et al. proposed a model of lesion development in which α-synuclein appears in the dorsal medullary vagus nucleus in the early stages of the disease and then expands from the midbrain to the limbic system and neocortex in patients with Parkinson’s disease [29]. Here, SNCA is linked to Parkinson disease.